Ultraexpensive gene therapies, industry interests and the right to health: the case of onasemnogene abeparvovec in Brazil

• Huseyin Naci,
• Anita K Wagner,
• Adriana Mitsue Ivama-Brummell,
• Vera Lúcia Edais Pepe

Affiliations

Huseyin Naci

associate professor of health policy

Anita K Wagner

2Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA

Adriana Mitsue Ivama-Brummell

Executive Secretariat of the Drug Market Regulation Chamber, Brazilian Health Regulatory Agency, Brasília, Distrito Federal, Brazil

Vera Lúcia Edais Pepe

National School of Public Health Sergio Arouca, Department of Health Administration and Planning, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil